Reaffirmed: Biogen Inc (NASDAQ:BIIB) Hold Rating Maintained at Robert W. Baird; $290.0 Target in Place

January 21, 2018 - By Darrin Black

 Reaffirmed: Biogen Inc (NASDAQ:BIIB) Hold Rating Maintained at Robert W. Baird; $290.0 Target in Place

Investors sentiment increased to 1.13 in 2017 Q3. Its up 0.25, from 0.88 in 2017Q2. It increased, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported.

Cetera Advisor owns 0.04% invested in Biogen Inc. (NASDAQ:BIIB) for 2,635 shares. Rhenman & Prns Asset owns 22,000 shares or 0.88% of their US portfolio. Parametrica Management holds 647 shares or 0.09% of its portfolio. Eqis Cap Management Incorporated reported 6,738 shares or 0.12% of all its holdings. Twin Focus Capital Prns Limited Liability Com owns 839 shares for 0.14% of their portfolio. Icon Advisers Co has invested 0.13% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Fmr Ltd Llc owns 7.15 million shares. Oak Assoc Limited Oh invested 0.35% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Main Street Research Ltd Liability has 3,544 shares. Rafferty Asset Management Ltd Limited Liability Company owns 4,867 shares or 0.03% of their US portfolio. Quantbot Techs Limited Partnership has 3,909 shares for 0.12% of their portfolio. Ubs Asset Management Americas Inc, Illinois-based fund reported 791,847 shares. Ashfield Capital Ptnrs Llc has invested 0.1% in Biogen Inc. (NASDAQ:BIIB). Portfolio Solutions Lc invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Mogy Joel R Invest Counsel stated it has 0.34% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

Since January 9, 2018, it had 0 buys, and 1 sale for $1.92 million activity.

Biogen Inc (NASDAQ:BIIB) Rating Reaffirmed

New York: In a report revealed to clients on 30 October, Robert W. Baird reconfirmed their Hold rating on Biogen Inc (NASDAQ:BIIB) shares. They now have a $290.0 TP on the firm. Robert W. Baird’s target indicates a potential downside of -15.31 % from the company’s close price.

Investors sentiment increased to 1.13 in 2017 Q3. Its up 0.25, from 0.88 in 2017Q2. It increased, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported.

Cetera Advisor owns 0.04% invested in Biogen Inc. (NASDAQ:BIIB) for 2,635 shares. Rhenman & Prns Asset owns 22,000 shares or 0.88% of their US portfolio. Parametrica Management holds 647 shares or 0.09% of its portfolio. Eqis Cap Management Incorporated reported 6,738 shares or 0.12% of all its holdings. Twin Focus Capital Prns Limited Liability Com owns 839 shares for 0.14% of their portfolio. Icon Advisers Co has invested 0.13% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Fmr Ltd Llc owns 7.15 million shares. Oak Assoc Limited Oh invested 0.35% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Main Street Research Ltd Liability has 3,544 shares. Rafferty Asset Management Ltd Limited Liability Company owns 4,867 shares or 0.03% of their US portfolio. Quantbot Techs Limited Partnership has 3,909 shares for 0.12% of their portfolio. Ubs Asset Management Americas Inc, Illinois-based fund reported 791,847 shares. Ashfield Capital Ptnrs Llc has invested 0.1% in Biogen Inc. (NASDAQ:BIIB). Portfolio Solutions Lc invested 0% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Mogy Joel R Invest Counsel stated it has 0.34% of its portfolio in Biogen Inc. (NASDAQ:BIIB).

Since January 9, 2018, it had 0 buys, and 1 sale for $1.92 million activity.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 31 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Biogen Idec Inc. has $450 highest and $268 lowest target. $353.21’s average target is 3.15% above currents $342.41 stock price. Biogen Idec Inc. had 97 analyst reports since July 23, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 30 by Jefferies. Mizuho upgraded the shares of BIIB in report on Tuesday, October 17 to “Buy” rating. Credit Suisse initiated the stock with “Neutral” rating in Wednesday, January 20 report. The firm earned “Outperform” rating on Wednesday, June 29 by Bernstein. The firm earned “Buy” rating on Monday, July 27 by Argus Research. Raymond James downgraded the stock to “Market Perform” rating in Thursday, September 21 report. The rating was maintained by Morgan Stanley on Wednesday, July 26 with “Equal-Weight”. The rating was maintained by SunTrust with “Buy” on Monday, October 23. The stock of Biogen Inc. (NASDAQ:BIIB) has “Hold” rating given on Wednesday, October 25 by RBC Capital Markets. On Tuesday, September 1 the stock rating was initiated by Raymond James with “Strong-Buy”.

The stock decreased 0.59% or $2.03 during the last trading session, reaching $342.41. About 1.23M shares traded or 0.25% up from the average. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 21, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on January, 25. They expect $5.52 earnings per share, up 9.52 % or $0.48 from last year’s $5.04 per share. BIIB’s profit will be $1.17 billion for 15.51 P/E if the $5.52 EPS becomes a reality. After $6.31 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts -12.52 % negative EPS growth.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $72.41 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 21.04 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

More news for Biogen Inc. (NASDAQ:BIIB) were recently published by: Fool.com, which released: “Will 2018 Be Biogen Inc.’s Best Year Yet?” on January 14, 2018. Marketwatch.com‘s article titled: “Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other …” and published on January 19, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: